A Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects With Metastatic ErbB2 Positive Breast Cancer

NCT00849329 PHASE1 COMPLETED

This study will characterize the effect of elevated gastric pH mediated by the proton-pump inhibitor, esomeprazole, on the relative bioavailability of lapatinib in subjects with metastatic ErbB2 positive breast cancer.

Details

Lead sponsor	GlaxoSmithKline
Phase	PHASE1
Status	COMPLETED
Enrolment	12
Start date	Tue Mar 10 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Nov 24 2009 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Neoplasms, Breast

Interventions

• lapatinib
• lapatinib plus esomeprazole

Countries

United States, Spain, South Korea